Source PharmaTimes: “Siponimod is the first investigational medicine to show a significant delay in disability progression in typical SPMS patients,” said Paul Hudson, chief executive of Novartis Pharmaceuticals. “We are closely working with the FDA and EMA to ensure siponimod is available for patients as soon as possible.”
Source PharmaTimes: “Siponimod is the first investigational medicine to show a significant delay in disability progression in typical SPMS patients,” said Paul Hudson, chief executive of Novartis Pharmaceuticals. “We are closely working with the FDA and EMA to ensure siponimod is available for patients as soon as possible.”
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
Secondary progressive multiple sclerosis (SPMS) is characterised by continuous worsening of neurological function over time, independent of relapses.
Most people with relapsing-remitting forms of MS will eventually go on to develop SPMS; on average, around 65 percent will develop SPMS 15 years after being diagnosed, according to the MS Society. Read on.
